Open AccessVernakalant for Cardioversion of Recent-Onset Atrial Fibrillation in the Emergency Department: The SPECTRUM Study
Author(s) -
Johan-Emil Bager,
Alfonso Martı́n,
José Dalmau,
Alexander Simon,
José Luís Merino,
Beate Ritz,
Juha Hartikainen
Publication year - 2022
Publication title -
cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.547
H-Index - 63
eISSN - 1421-9751
pISSN - 0008-6312
DOI - 10.1159/000526831
Subject(s) - medicine , cardioversion , emergency department , atrial fibrillation , atrial flutter , adverse effect , cardiology , bradycardia , anesthesia , sinus bradycardia , amiodarone , heart rate , psychiatry , blood pressure
Intravenous vernakalant is a therapeutic option for symptomatic, recent-onset atrial fibrillation (AF). This secondary analysis from the large SPECTRUM study assessed the safety and effectiveness of vernakalant when used in the emergency department setting (ED group) or in an inpatient hospital setting (non-ED group).